Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib

World Journal of Gastroenterology

Volumn 16, Issue 28, 2010, Pages 3592-3596

  Wich, Christina ^a   Agaimy, Abbas ^a   Strobel, Deike ^a   Wissniowski, Thaddäus Till ^a   Hartmann, Arndt ^a   Ocker, Matthias ^a,b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Angiogenesis; Bevacizumab; Hepatocellular carcinoma; Sorafenib

Indexed keywords

BEVACIZUMAB; GEMCITABINE; LOPERAMIDE; OXALIPLATIN; SORAFENIB; VITAMIN K GROUP; WATER OIL CREAM;

ADULT; ANAMNESIS; ARTICLE; BLOOD CLOTTING DISORDER; CANCER GROWTH; CASE REPORT; CLEAVAGE ERYTHEMA; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHEMA; FACE ERYTHEMA; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HUMAN TISSUE; KIDNEY DYSFUNCTION; LABORATORY TEST; LIVER BIOPSY; LIVER CELL CARCINOMA; MALE; METASTASIS; MOUTH ULCER; PANCYTOPENIA; SIDE EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 77955115503     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i28.3592     Document Type: Article

References (27)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576
2. Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 2007; 11: 191-207, x-xi
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750
4. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70
6. Okamoto K, Neureiter D, Ocker M. Biomarkers for novel targeted therapies of hepatocellular carcinoma. Histol Histopathol 2009; 24: 493-502
7. Greten TF, Korangy F, Manns MP, Malek NP. Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer 2009; 100: 19-23
8. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300
9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
10. Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43: 489-495
11. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12: 1175-1181
12. Lopez RR Jr, Pan SH, Hoffman AL, Ramirez C, Rojter SE, Ramos H, McMonigle M, Lois J. Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma. Arch Surg 2002; 137: 653-657; discussion 657-658
13. Khodjibekova M, Szyszko T, Khan S, Nijran K, Tait P, Al-Nahhas A. Selective internal radiation therapy with Yttrium-90 for unresectable liver tumours. Rev Recent Clin Trials 2007; 2: 212-216
14. Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Gruenberger T, Haller D, Haustermans K, Hoff P, Kerr D, Labianca R, Moore M, Nordlinger B, Ohtsu A, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, van de Velde C. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol 2009; 20 Suppl 7: vii1-vii6
15. Katyal S, Oliver JH 3rd, Peterson MS, Ferris JV, Carr BS, Baron RL. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000; 216: 698-703
16. Talwalkar JA, Gores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 2004; 127: S126-S132
17. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338
18. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 1898-1903
19. Finn RS, Zhu AX. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 2009; 9: 503-509
20. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008; 26: 3709-3714
21. Lee JM, Sarosy GA, Annunziata CM, Azad N, Minasian L, Kotz H, Squires J, Houston N, Kohn EC. Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br J Cancer 2010; 102: 495-499
22. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008; 62: 779-786
23. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28: 1779-1802
24. Senan S, Smit EF. Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist 2007; 12: 465-477
25. Hsieh CH, Jeng KS, Lin CC, Chen CK, Liu CY, Lin CP, Tai HC, Wang CH, Shueng PW, Chen YJ. Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. Clin Drug Investig 2009; 29: 65-71
26. Kasibhatla M, Steinberg P, Meyer J, Ernstoff MS, George DJ. Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. Clin Genitourin Cancer 2007; 5: 291-294
27. Gay HA, Cavalieri R, Allison RR, Finley J, Quan WD Jr. Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy. Dermatol Online J 2007; 13: 6